← All trials
NCT02207816
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2014
- Primary completion
- Jan 31, 2017
- Completion date
- Jan 31, 2017
- First posted
- Aug 4, 2014
- Last posted
- Nov 25, 2019
- Enrollment
- 3084
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.